Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Narjust Duma(Rutgers, The State University of New Jersey), Alex A. Adjei(Cleveland Clinic), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Konstantinos Leventakos(Rutgers, The State University of New Jersey), Ronald S. Go(Mayo Clinic), Candace L. Haddox(Rutgers, The State University of New Jersey), Aaron S. Mansfield(Mayo Clinic), Yucai Wang(Mayo Clinic), Miguel González Vélez(Rutgers, The State University of New Jersey), Jesus Vera Aguilera(Rutgers, The State University of New Jersey), Jonas Paludo(WinnMed)
Cited by 447
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829